I was hoping to keep COVID-19 out of this piece, but new things keep flooding in, and I can’t totally ignore them. However, I’ll save them to the end of the story. They are both “good news,” more or less, and I like to leave you with a bit of cheer, when possible. Sleep and […]
Articles
Before I launch into the topics of the day, I am going to share with you an opinion piece about the recent CDC guidelines. I find myself in complete concurrence with this piece, which was posted a few weeks ago on MedPage Today, a medical website that is a very helpful source of information for […]
Everyone loves a good “this’ll cure Alzheimer’s!” story… both because we all know someone who has been touched by this awful disease, and because we know that a cure for Alzheimer’s would likely be a multi-billion-dollar drug. So the pundits tease early-stage hopefuls quite often, they fail almost all the time, and we keep hoping […]
Many of the comments to these Doc Gumshoe pieces go like this: “What do you know about such-and-such a drug, or about what this or that person (usually a physician) has to say about cancer, or heart disease, or (especially these days) about COVID-19?” My right-off-the-bat response to most of these would usually be “not […]
I got several reader questions this week about a new recommendation from Dave Lashmet at Stansberry — it looks like this was issued as a recommendation for regular Stansberry Investment Advisory subscribers, not one of Lashmet’s more expensive biotech-focused newsletters, and it’s very light on clues… but let’s see if we can give you anything […]
The many welcome comments to the Alzheimer’s piece that posted a couple of weeks ago prompt me to supply answers (if I am able to do that), but also set my mind to wandering on the fringes of a number of issues that may be of interest to the Gumshoe constituency. Anavex 2-73 At the […]
“This Wednesday, September 5 Tuesday, May 28, a group of scientists will take the stage at a prestigious medical conference… “And announce to the world the potential end of disease as we know it.” That’s the attention-getting part of Ray Blanco’s latest teaser ad for his FDA Trader newsletter that Gumshoe readers have been asking […]
Ray Blanco makes (part of) his living looking for biotech moonshots, like most biotech-focused newsletter writers — and like his predecessor at Agora’s biotech and emerging tech-focused newsletter Breakthrough Technology Alert, he has often touted companies that are trying to end the scourge of Alzheimer’s Disease. Why? Well, two main reasons: First, and by far […]
We are always, always tempted by anything that promises hope to sufferers of Alzheimer’s Disease and their families… not just because we’re humanitarians and love people, and have seen the pain of this disease, but because Alzheimer’s treatment is by far the largest (mostly) unmet medical need in the US, both because the population of […]
I love Thanksgiving. I love that we all try to remember to slow down our lives a little bit, spend time with family and friends, and give thanks for the incredible blessings most of us enjoy and take for granted. But I also love naming our annual “Turkey” teaser stock. What is this? Well, if […]
As a reformed academic, I have it hard-wired in my brain that work should cease for the week between Christmas and New Year’s Day — Stock Gumshoe will be running on autopilot starting this afternoon, and we’re not likely to have much in the way of new articles posted until next year (unless you want […]
Alzheimer’s Wrap-Up[ed note: Michael Jorrin, who I like call “Doc Gumshoe,” is a longtime medical writer who shares his thoughts with us a couple times a month — his articles are non-financial in nature, his words and opinions are his own, and you can see his bio and his past pieces here. Enjoy!] Indulge me while […]
I know I’ve said this before, and sometimes it’s a lie: I’m going to try to keep this one brief. Agora Financial’s FDA Trader service has a new pitch out — which normally might not get that much attention, since everyone is suddenly terrified of biotech stocks after a brutal month or two — but […]
That’s a subtle headline, right? I already issued a bit of a “brain dump” for the Irregulars this week, on Wednesday instead of Friday, but I couldn’t resist taking a little look at this latest teaser pitch from Patrick Cox for his Transformational Technology Alert. Quite a few readers have been asking about it, and […]
Neither of the two picks that Patrick Cox has lately been teasing are new — but I’m getting a lot of questions about both of them so I thought I’d provide a couple quick answers on this lovely Friday afternoon. Both of these teaser ads are designed to encourage investors to subscribe to his Breakthrough […]
I always feel a swell of optimism when I read a teaser ad from Patrick Cox — something about his relentless happy-facing about the teensy tiny technology and biotech companies he loves just stirs me up a little bit, reminds me that the reason many of us dabble in microcap stocks, little mining companies, new […]
Well, yesterday we went through the first two picks that Patrick Cox is teasing as his “7 breakthrough companies” that will bring us our next “printing press moment” and change the world (while inflating your wallet). If you want to catch up with the rest of the group, that article is here. So let’s move […]
This teaser ad that I started seeing about ten days ago has both promise for the families of Alzheimer’s sufferers and, of course, the promise of riches for those who get in early on the next hot biotech with a cure for Alzheimer’s Disease. The ad is from Brian Hicks, for a new letter that […]
We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.
More Info
Comments
Have you looked at the promising phase 2 clinical results from both Cassava Sciences (SAVA) and Annavex Life Sciences (A...
Doc - I thank you for your articles but I can't figure out how you keep lacking for the Anavex AVXL. They are much furth...
In both SAVA and AVXL. Personal and financial reasons. Getting a lot of added interest today with BIIB approval....
I have been telling everyone here and elsewhere AVXL for the past 3 years!...
you never know. I mentioned AVXL on here for a long time and made a lot of $$$$ when it went to $28...
Own AVXL and SAVA. Purchased both because of the possibility to help my family battle Alzheimer's disease. Believe that ...
Thanks again for thoughtful and informative comments on avxl and quercetin. I have some stock in avxl and have done...
ok , CRTX is for Alzheimer's the stock is good to buy right now , going up for short, medium ,and long term, about 1 ...
Anavex Life Sciences AVXL is the company and ANAVEX®2-73 (Blarcamesine)is the drug I would like you to investigate fo...
I keep telling people AVXL I touted it when it was .60 and it will go to $15 if it gets to phase 3...
Doc, I found this comment very interesting: "Memantine (Namenda), from Forest Pharmaceuticals, an antagonist of N-methy...
[“‘Wonder if some are sharing stock research, thus wearing running shoes; not their own gum shoes??!’”] Looks...
Many interesting comments in response to that Alzheimer’s piece. I’ll try to respond to as many as I can. And ma...